JP2015504307A - 特発性肺線維症を診断および治療する方法 - Google Patents

特発性肺線維症を診断および治療する方法 Download PDF

Info

Publication number
JP2015504307A
JP2015504307A JP2014542588A JP2014542588A JP2015504307A JP 2015504307 A JP2015504307 A JP 2015504307A JP 2014542588 A JP2014542588 A JP 2014542588A JP 2014542588 A JP2014542588 A JP 2014542588A JP 2015504307 A JP2015504307 A JP 2015504307A
Authority
JP
Japan
Prior art keywords
seq
mir
micrornas
sequence
ipf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014542588A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015504307A5 (https=
Inventor
カール コッセン，
カール コッセン，
シャルレーン リム，
シャルレーン リム，
シャオリ チン，
シャオリ チン，
ウイリアムソン ジーグラー ブラッドフォード，
ウイリアムソン ジーグラー ブラッドフォード，
スコット ディー． セイワート，
スコット ディー． セイワート，
Original Assignee
インターミューン， インコーポレイテッド
インターミューン， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インターミューン， インコーポレイテッド, インターミューン， インコーポレイテッド filed Critical インターミューン， インコーポレイテッド
Publication of JP2015504307A publication Critical patent/JP2015504307A/ja
Publication of JP2015504307A5 publication Critical patent/JP2015504307A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Nuclear Medicine (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2014542588A 2011-11-22 2012-11-21 特発性肺線維症を診断および治療する方法 Pending JP2015504307A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161562770P 2011-11-22 2011-11-22
US61/562,770 2011-11-22
US201261648548P 2012-05-17 2012-05-17
US61/648,548 2012-05-17
PCT/US2012/066221 WO2013078283A1 (en) 2011-11-22 2012-11-21 Methods of diagnosing and treating idiopathic pulmonary fibrosis

Publications (2)

Publication Number Publication Date
JP2015504307A true JP2015504307A (ja) 2015-02-12
JP2015504307A5 JP2015504307A5 (https=) 2016-01-21

Family

ID=47258131

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014542588A Pending JP2015504307A (ja) 2011-11-22 2012-11-21 特発性肺線維症を診断および治療する方法

Country Status (11)

Country Link
US (1) US20130150426A1 (https=)
EP (1) EP2783016A1 (https=)
JP (1) JP2015504307A (https=)
CN (1) CN103987858A (https=)
AU (1) AU2012340698A1 (https=)
BR (1) BR112014012288A2 (https=)
CA (1) CA2853136A1 (https=)
EA (1) EA201491019A1 (https=)
HK (2) HK1201298A1 (https=)
MX (1) MX2014006130A (https=)
WO (1) WO2013078283A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017143810A (ja) * 2016-02-19 2017-08-24 学校法人慶應義塾 抗酸菌症又は抗酸菌感染のバイオマーカー
JP2021129513A (ja) * 2020-02-19 2021-09-09 国立医薬品食品衛生研究所長 びまん性肺胞障害型薬剤性間質性肺炎のｍｉＲＮＡ診断バイオマーカー

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2986538B1 (fr) * 2012-02-06 2016-03-11 Centre Nat Rech Scient Utilisation du mir-199a-5p de ses cibles et/ou inhibiteurs pour le diagnostic, le pronostic et le traitement des pathologies fibroproliferatives
WO2013174692A1 (en) * 2012-05-22 2013-11-28 Ruprecht-Karls-Universität Heidelberg Therapeutic micro rna targets in chronic pulmonary diseases
CN104560991B (zh) * 2013-10-10 2021-02-26 复旦大学附属妇产科医院 用于防治人乳头瘤病毒感染和宫颈癌的微小rna
GB201403489D0 (en) * 2014-02-27 2014-04-16 Univ London Queen Mary Biomarkers for endometriosis
US20170226507A1 (en) * 2014-05-05 2017-08-10 The Brigham And Women's Hospital, Inc. Coordinate control of pathogenic signaling by the mir-130/301 family in pulmonary hypertension and fibroproliferative diseases
CN105132525B (zh) * 2014-05-29 2018-11-09 中国医学科学院基础医学研究所 miRNA分子在精神分裂症的诊断和预后中的用途
EP2957634A1 (en) * 2014-06-20 2015-12-23 Consejo Superior De Investigaciones Científicas Compounds for prevention and/or treatment of fibrotic diseases
US9376681B2 (en) 2014-09-08 2016-06-28 MiRagen Therapeutics, Inc. miR-29 mimics and uses thereof
US20170298352A1 (en) * 2014-09-30 2017-10-19 Research Institute at Nationwide Children's Hospit al Compositions and methods for treating hepatic fibrosis
CN112063714A (zh) * 2014-10-28 2020-12-11 广州复能基因有限公司 一种与结直肠癌相关的miRNA及其应用
CN104450707B (zh) * 2014-12-25 2017-08-29 厦门大学 一种血清miRNA生物标志物的应用
CN104694542A (zh) * 2015-03-19 2015-06-10 中国人民解放军第四军医大学 一种促进组织工程骨血管化的 microRNA 及其应用
CN105079808B (zh) * 2015-05-22 2018-04-03 重庆医科大学 miR590的用途及其相关药物
JP2018517418A (ja) * 2015-06-15 2018-07-05 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 情動障害の診断および治療の方法
GB201513128D0 (en) * 2015-07-24 2015-09-09 Sense Biodetection Ltd Nucleic acid detection method
CN105106972A (zh) * 2015-08-13 2015-12-02 常州市第一人民医院 miR-338-5p及靶向作用于miR-338-5p核酸制剂的新用途
CN105169393B (zh) * 2015-08-31 2018-07-03 北京泱深生物信息技术有限公司 miRNA-548a-3p抗急性髓系白血病中的应用
CN109477144B (zh) 2015-09-29 2022-12-09 国家儿童医院研究所 用于检测肝脏纤维化和对疗法的响应性的方法
CN106011303B (zh) * 2016-08-08 2019-05-24 南京市妇幼保健院 一种与儿童肥胖相关的血清或血浆miRNA标志物及其应用
WO2018170622A1 (zh) * 2017-03-18 2018-09-27 深圳市博奥康生物科技有限公司 一种同步下调微小rna-152和微小rna-185表达的方法
WO2018170652A1 (zh) * 2017-03-19 2018-09-27 深圳市博奥康生物科技有限公司 多重敲低三种miRNA的Tud RNA及其应用
CN107236799B (zh) * 2017-06-15 2020-06-09 昆明医科大学第六附属医院 一种肾纤维化miRNA标记物
CN108186564B (zh) * 2018-01-03 2020-06-02 上海市肿瘤研究所 一种肿瘤微环境响应型基因纳米胶束及其制备方法和应用
CN108611414A (zh) * 2018-04-26 2018-10-02 北京工业大学 新的靶向肿瘤微环境与肺癌干细胞相互作用的miRNA的检测及应用
CN109486911A (zh) * 2018-11-28 2019-03-19 上海纳米技术及应用国家工程研究中心有限公司 基于滚环扩增和DNA折纸术检测microRNAs的方法
CN109825575B (zh) * 2019-04-08 2026-01-30 首都医科大学附属北京胸科医院 辅助诊断结核病的miRNA标志物及其应用
CN110055322A (zh) * 2019-05-12 2019-07-26 青岛大学 用于急性心肌梗死诊断的循环miRNA标志物及其应用
PH12021553079A1 (en) * 2019-06-14 2023-09-11 Cardior Pharmaceuticals Gmbh Treatment of heart failure in human subjects
US20220313723A1 (en) 2019-07-16 2022-10-06 Université de Liège Extracellular vesicles containing mir-142-3p to treat fibrosing diseases
CN116042623A (zh) * 2023-02-01 2023-05-02 浙江大学医学院附属第一医院 一种作为生物标志物的微小rna及在皮肤光老化中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009542608A (ja) * 2006-06-29 2009-12-03 アステックス・セラピューティクス・リミテッド 医薬組合せ剤
WO2010039502A2 (en) * 2008-09-23 2010-04-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Micrornas in idiopathic pulmonary fibrosis
WO2010137160A1 (ja) * 2009-05-29 2010-12-02 株式会社 静岡カフェイン工業所 肺線維症の予防もしくは治療薬
JP2011516410A (ja) * 2008-02-27 2011-05-26 ユリウス・マクシミリアンス−ウニヴェルジテート・ヴュルツブルク 診断および治療のためのミクロＲＮＡ（ｍｉＲＮＡ）および下流標的
WO2011069094A1 (en) * 2009-12-04 2011-06-09 Intermune, Inc. Methods of administering pirfenidone therapy

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5430136A (en) 1984-10-16 1995-07-04 Chiron Corporation Oligonucleotides having selectably cleavable and/or abasic sites
US5124246A (en) 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5359100A (en) 1987-10-15 1994-10-25 Chiron Corporation Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers
US5310562A (en) 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5681697A (en) 1993-12-08 1997-10-28 Chiron Corporation Solution phase nucleic acid sandwich assays having reduced background noise and kits therefor
US5580731A (en) 1994-08-25 1996-12-03 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5681702A (en) 1994-08-30 1997-10-28 Chiron Corporation Reduction of nonspecific hybridization by using novel base-pairing schemes
US6090822A (en) 1995-03-03 2000-07-18 Margolin; Solomon B. Treatment of cytokine growth factor caused disorders
US6114353A (en) 1995-03-03 2000-09-05 Margolin; Solomon B. Compositions and method for treatment of lymphomas, leukemias, and leiomyomas
US5962478A (en) 1995-09-19 1999-10-05 Margolin; Solomon B. Inhibition of tumor necrosis factor α
US7785842B2 (en) 1996-03-26 2010-08-31 Oncomedx, Inc. Comparative analysis of extracellular RNA species
PT1258484E (pt) 2000-02-18 2009-04-03 Kyowa Hakko Kirin Co Ltd Novos compostos de isoxazol e de tiazol e sua utilização enquanto fármacos
US6956044B1 (en) 2000-02-21 2005-10-18 Margolin Solomon B Compositions and methods for treatment of epilepsy
WO2002062389A1 (en) 2001-02-08 2002-08-15 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
ATE448784T1 (de) 2002-02-14 2009-12-15 Pharmacia Corp Substituierte pyridinone als modulatoren für p38 map kinase
JP2005027804A (ja) 2003-07-10 2005-02-03 Konica Minolta Medical & Graphic Inc 診察支援システム、データ処理端末及びデータ処理プログラム
JP4692281B2 (ja) 2003-08-05 2011-06-01 味の素株式会社 新規アゾール化合物
CN100358872C (zh) 2003-11-14 2008-01-02 上海睿星基因技术有限公司 吡啶酮衍生物及其应用
JP5697297B2 (ja) 2004-05-14 2015-04-08 ロゼッタ ジノミクス リミテッド マイクロｎａｓおよびその使用
US20060292616A1 (en) 2005-06-23 2006-12-28 U.S. Genomics, Inc. Single molecule miRNA-based disease diagnostic methods
MX352516B (es) 2006-07-05 2017-04-06 Fibrotech Therapeutics Pty Ltd Compuestos terapeuticos.
WO2008157786A1 (en) 2007-06-20 2008-12-24 Auspex Pharmaceutical, Inc. Substituted n-aryl pyridinones as fibrotic inhibitors
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
CN101918594A (zh) * 2007-11-30 2010-12-15 俄亥俄州立大学研究基金会 肺癌中外周血中的微rna表达特征谱和靶向
WO2009099901A1 (en) 2008-02-01 2009-08-13 Amira Pharmaceuticals, Inc. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
WO2009102893A2 (en) 2008-02-14 2009-08-20 Amira Pharmaceuticals, Inc. CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors
WO2010054386A2 (en) * 2008-11-10 2010-05-14 Battelle Memorial Institute Methods, compositions, and devices utilizing microrna to determine physiological conditions
US8455499B2 (en) 2008-12-11 2013-06-04 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
GB2466121B (en) 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
AP2011005824A0 (en) 2009-01-26 2011-08-31 Intermune Inc Methods for treating acute myocardial infarctions and associated disorders.
GB2470833B (en) 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
CN102574822A (zh) 2009-08-04 2012-07-11 阿米拉制药公司 作为溶血磷脂酸受体拮抗剂的化合物
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009542608A (ja) * 2006-06-29 2009-12-03 アステックス・セラピューティクス・リミテッド 医薬組合せ剤
JP2011516410A (ja) * 2008-02-27 2011-05-26 ユリウス・マクシミリアンス−ウニヴェルジテート・ヴュルツブルク 診断および治療のためのミクロＲＮＡ（ｍｉＲＮＡ）および下流標的
WO2010039502A2 (en) * 2008-09-23 2010-04-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Micrornas in idiopathic pulmonary fibrosis
WO2010137160A1 (ja) * 2009-05-29 2010-12-02 株式会社 静岡カフェイン工業所 肺線維症の予防もしくは治療薬
WO2011069094A1 (en) * 2009-12-04 2011-06-09 Intermune, Inc. Methods of administering pirfenidone therapy

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
KASS, DANIEL, J. ET AL.: ""Evolving genomic approaches to idiopathic pulmonary fibrosis: moving beyond genes"", CLIN. TRANSL. SCI., vol. 4, JPN6016035431, October 2011 (2011-10-01), pages 372 - 379, ISSN: 0003401632 *
MI, SHUANGLI ET AL.: ""Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia"", PROC. NATL. ACAD. SCI. U. S. A., vol. 107, JPN6016035434, 2010, pages 3710 - 3715, XP055533260, ISSN: 0003401635, DOI: 10.1073/pnas.0914900107 *
OAK, SAMEER R. ET AL.: ""A micro RNA processing defect in rapidly progressing idiopathic pulmonary fibrosis"", PLOS ONE, vol. Vol. 6: e21253, JPN6016035432, 21 June 2011 (2011-06-21), pages 1 - 12, ISSN: 0003401633 *
PANDIT, KUSUM V. ET AL.: ""Inhibition and role of let-7d in idiopathic pulmonary fibrosis"", AM. J. RESPIR. CRIT. CARE MED., vol. 182, JPN6016035435, 2010, pages 220 - 229, XP055031319, ISSN: 0003401636, DOI: 10.1164/rccm.200911-1698OC *
ZHANG, W. ET AL.: ""Profiling of microrna expression in idiopathic pulmonary fibrosis"", AM. J. RESPIR. CRIT. CARE MED., vol. Vol. 183, No. 1, Supp. Meeting Abstracts, JPN6016035433, May 2011 (2011-05-01), pages 6004, ISSN: 0003401634 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017143810A (ja) * 2016-02-19 2017-08-24 学校法人慶應義塾 抗酸菌症又は抗酸菌感染のバイオマーカー
JP2021129513A (ja) * 2020-02-19 2021-09-09 国立医薬品食品衛生研究所長 びまん性肺胞障害型薬剤性間質性肺炎のｍｉＲＮＡ診断バイオマーカー
JP7392224B2 (ja) 2020-02-19 2023-12-06 国立医薬品食品衛生研究所長 びまん性肺胞傷害型薬剤性間質性肺炎のｍｉＲＮＡ診断バイオマーカー

Also Published As

Publication number Publication date
CN103987858A (zh) 2014-08-13
AU2012340698A1 (en) 2014-04-24
MX2014006130A (es) 2015-04-13
US20130150426A1 (en) 2013-06-13
HK1201298A1 (en) 2015-08-28
BR112014012288A2 (pt) 2017-05-23
WO2013078283A1 (en) 2013-05-30
EP2783016A1 (en) 2014-10-01
CA2853136A1 (en) 2013-05-30
HK1201299A1 (en) 2015-08-28
EA201491019A1 (ru) 2014-08-29

Similar Documents

Publication Publication Date Title
JP2015504307A (ja) 特発性肺線維症を診断および治療する方法
AU2012265177B2 (en) Methods and devices for prognosis of cancer relapse
EP3506912B1 (en) Micrornas as biomarkers for endometriosis
Del Vescovo et al. MicroRNAs as lung cancer biomarkers
EP2559772B1 (en) Methods for determining a hepatocellular carcinoma subtype
AU2010234806B2 (en) Differentially expressed microRNAs as biomarkers for the diagnosis and treatment of Sjogren's syndrome
US20140243240A1 (en) microRNA EXPRESSION PROFILING OF THYROID CANCER
US20110160290A1 (en) Use of extracellular rna to measure disease
US20100202973A1 (en) Microrna molecules associated with inflammatory skin disorders
AU2012265177A1 (en) Methods and devices for prognosis of cancer relapse
US20130017964A1 (en) Methods to Identify Chronic Lymphocytic Leukemia Disease Progression
JP5931897B2 (ja) マイクロｒｎａ−２１、ミスマッチ修復および結腸直腸癌に関連する物質および方法
Wang et al. Circular RNA in invasive and recurrent clinical nonfunctioning pituitary adenomas: expression profiles and bioinformatic analysis
Zhang et al. The complex roles of microRNAs in the metastasis of renal cell carcinoma
WO2011154008A1 (en) Microrna classification of thyroid follicular neoplasia
Torres et al. MicroRNAs and their role in gynecological tumors
WO2026050201A1 (en) Endogenous reference rna and uses thereof
Goolam Hoosen Identification and characterisation of micrornas involved in the pathogenesis of HIV–associated non-Hodgkin's lymphoma
Benway Defining a microRNA-mRNA targetome for calcineurin inhibitor induced nephrotoxicity
HK40011172B (en) Micrornas as biomarkers for endometriosis
HK40011172A (en) Micrornas as biomarkers for endometriosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160915

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170306